

13th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Meeting
June 2 – 5, 2010
River Rock Casino Resort
Vancouver (Richmond), British Columbia, Canada

New Frontiers in Pharmaceutical Sciences

Chair: Laszlo Endrenyi
Scientific Chairs: Robert Young and Christine Allen
Local Organizing Committee: David Kwok (Chair), Frank Abbott, Athena Juneson, Dave Marchand

PROGRAM

Wednesday, June 2, 2010

3:30-7:00 PM	Registration (CSPS & CPERC Desks - Lower Theatre Lobby)
5:30-7:00 PM	Welcome Wine and Cheese Reception - Joint CSPS & AFPC (Upper Theatre Lobby) Exhibition Opens. (SPONSORED BY CONTROLLED RELEASE SOCIETY-CANADIAN CHAPTER)

Thursday, June 3, 2010

Continental Breakfast in Exhibit area (Upper Theatre Lobby)	
7:30 AM	Registration (Lower Theatre Lobby)
8:00 AM - 6:00 PM	Poster Presentations (Upper and Lower Theatre Lobbies)
8:30	PLENARY SESSION (Whistler Ballroom A & B) Chair: Laszlo Endrenyi, University of Toronto, Toronto, ON (SESSION SPONSORED BY FMC BIOPOLYMER)
8:30	Welcome - Dr. Laszlo Endrenyi, CSPS President
8:40	Keynote Speaker: Pieter Cullis, University of British Columbia/CDRD, Vancouver, BC "Lipid-Based Nanomedicines: Applications to Conventional Drugs and Genetic Drugs"
9:30-10:00	Poster Viewing and Break
10:00-12:30	Session I a (Whistler Ballroom A) Session I b (Whistler Ballroom B)
	PRODRUGS AS NOVEL THERAPIES Chair: Robert Young, Simon Fraser University, Burnaby, BC
	NEW ADVANCES IN DRUG METABOLISM AND DISPOSITION: GENETIC VERSUS ENVIRONMENTAL INFLUENCES Chair: Micheline Piquette-Miller, University of Toronto, Toronto, ON
10:00-10:40	PEG-based Prodrugs Improve the Anticancer Activity of Small Molecule Cytotoxics Hong Zhao, Enzon Pharmaceuticals, Piscataway, NJ
	Altered Drug Metabolism and Transport in Cancer and Cachexia Graham Robertson, University of Sydney, ANZAC Research Institute, Sydney, Australia

10:40-11:20	Role of Prodrug Design in Lead Optimization Strategy Reza Oliyai, Gilead Sciences, Foster City, CA	Pharmacogenomics of Drug Disposition: Theory and Application Anahita Bhatena, Abbott Laboratories, Abbott Park, IL
11:20-11:50	Development of a Weak-Base Docetaxel Derivative That Can be Loaded into Liposomal Nanoparticles Norbert Maurer, Centre for Drug Research & Development, Vancouver, BC	Genetic and Environmental Regulation of Drug Metabolizing Enzymes and Transporters by Nuclear Receptors Wen Xie, University of Pittsburgh, Pittsburgh, PA
11:50-12:10	Novel Bone-targeting Prostaglandin EP4 Receptor Agonist-Bisphosphonate Pro-drug Conjugates as Dual Action Therapies for Treatment and Reversal of the Effects of Osteoporosis Robert Young, Simon Fraser University, Burnaby, BC	Regulation of Drug Transporters and its Impact on Drug Response and Kinetics Micheline Piquette-Miller, University of Toronto, Toronto, ON
12:10-12:20	Trainee presentations: -Non-ulcerogenic Effective Non-steroidal Anti-inflammatory Prodrugs of Aspirin, Ibuprofen, and Indomethacin: Is Nitric Oxide-release Required? Sarthak Jain, University of Alberta, Edmonton, AB	Trainee presentations: -The Effect of Nrf2 Knockout on the Constitutive Expression of Drug Metabolizing Enzymes in C57Bl/6 Mice Livers Anwar Anwar-Mohamed, University of Alberta, Edmonton, AB
12:20-12:30	-Bone-targeting Salmon Calcitonin Analogue: Synthesis, Characterization and <i>in vivo</i> Evaluation Krishna Hari Bhandari, University of Alberta, Edmonton, AB	-Naturally Occurring Variants of Human Aldo-keto Reductases Alter <i>in vitro</i> Metabolism of Doxorubicin and Daunorubicin Onkar S. Bains, University of British Columbia, Vancouver, BC
12:40-2:00	Luncheon and CSPS Annual General Meeting - (Theatre) Poster viewing	
12:40-2:00	AFPC/CSPS Trainee Luncheon Session – Wayfinding in the Pharmaceutical Sciences: Challenges & Rewards of an Academic Career (Capilano & Birkenhead Rooms)	
2:00-5:00	Session II a (Whistler Ballroom A)	Session II b (Whistler Ballroom B)
	NEW DIRECTIONS IN CLINICAL APPLICATIONS OF DELIVERY SYSTEMS FOR CANCER TREATMENT AND DIAGNOSIS Chair: Afsaneh Lavasanifar, University of Alberta, Edmonton, AB Co-Chair: Christine Allen, University of Toronto, Toronto, ON (SESSION SPONSORED BY BAYER)	BIOMARKERS (FOR PRECLINICAL DEVELOPMENT, TOXICOLOGY, CLINICAL TRIALS) Chair: Bruce McManus, PROOF Centre of Excellence, Vancouver, BC
2:00-2:30	Opportunities for Combination Medical Devices in Local siRNA Delivery and Therapeutics David Grainger, University of Utah, Salt Lake City, UT	What Pharma Needs with Respect to Biomarkers – COPD as an Example Bruce Miller, GlaxoSmithKline, King of Prussia, PA
2:30-3:00	Polymeric Micelles for Combinatorial Drug Delivery Glen Kwon, University of Wisconsin, Madison, WI	What the Diagnostic Industry Can Offer Mike Pintek, Luminex Corporation, Austin, TX
3:00-3:30	Poster Viewing and Break	

3:30-4:00	Nanotechnology Applications in Cancer Diagnosis and Therapy Mansoor Amiji, Nanomedicine Education and Research Consortium, Northeastern University, Boston, MA	Biomarkers in Transplantation: From Purpose to Discovery and Validation of Signatures of Immune Rejection Bruce McManus, PROOF Centre of Excellence, Vancouver, BC
4:00-4:30	Targeted Nano-therapeutics for the Treatment of Resistant Cancers Afsaneh Lavasanifar, University of Alberta, Edmonton, AB	Bringing the Community Together for Efficient Biomarker Strategies Shawnmarie Mayrand-Chung, The Biomarkers Consortium, National Institutes of Health, Bethesda, MD
4:30-4:40	Trainee presentations: -Enhancement of Docetaxel Solubility via Conjugation of Formulation-Compatible Moieties Loan Huynh (Co-winner of Gattefossé Award), University of Toronto, Toronto, ON	Trainee presentations: Disease-drug interaction: Reduces Response to Verapamil Despite Increased Concentration in Active Crohn's Disease Forough Sanaee, University of Alberta, Edmonton, AB
4:40-4:50	-Design and Development of a New Family of Self-assembling Gene Delivery Nanoparticles using Cationic Amino Acid Substituted Gemini Surfactants Jagbir Singh, University of Saskatchewan, Saskatoon, SK	Inflammation Downregulates Angiotensin Converting Enzyme 2 in Rat Heart Sherif Hanafy, University of Alberta, Edmonton, AB
5:00 - 6:00	Reception & Poster Viewing - Joint CSPS/AFPC (Theatre Upper Floor Foyer) (RECEPTION SPONSORED BY MERCK)	

Friday, June 4, 2010		
Continental Breakfast in Exhibit area (Upper Theatre Lobby)		
8:00 AM Registration		
8:00 AM - 4:00 PM Poster Presentations (Upper and Lower Theatre Lobbies)		
7:00 - 8:20	CSPS/AFPC Trainee Breakfast Session: Career Mentoring (Chairman's Room)	
8:30-9:40	SESSION III (Whistler Ballroom A&B) AWARD WINNER PRESENTATIONS Chair: Elizabeth Vadas, InSciTech Inc., Dorval, QC	
	CSPS Leadership Award - Anne Tomalin, i3 CanReg Inc., Dundas, ON "CanReg: The Successful Convergence of Government, Academia and Industry" CSPS Leadership Award - Pieter Cullis, University of BC/CDRD, Vancouver, BC: "Adventures of a Serial Entrepreneur" GlaxoSmithKline Early Career Award - Carolyn Cummins, University of Toronto "The Liver X Receptors in the Regulation of Cholesterol and Glucose Metabolism"	
9:40-10:00	Poster Viewing and Break	
10:00-12:20	Session IV a (Whistler Ballroom A)	Session IV b (Whistler Ballroom B)
	siRNA AS <i>IN VIVO</i> THERAPEUTICS Chair: Pieter Cullis, University of British Columbia/CDRD, Vancouver, BC (SESSION SPONSORED BY MERCK)	ROLE OF LIPIDS IN MODIFYING ORAL AND PARENTERAL DRUG DELIVERY Chair: Kishor Wasan University of British Columbia, Vancouver, BC Co-Chair: Dion Brocks, University of Alberta, Edmonton, AB
10:00-10:30	Small Interfering RNA as a Therapeutic Modality Alan Sachs, Merck Research Laboratories/Sirna Therapeutics, San Francisco, CA	Lipid Based Formulations of Anticancer Drugs: What's In and What's Out Marcel Bally, BC Cancer Agency, Vancouver, BC

10:30-11:00	Progress in the Development Delivery Systems for siRNA Mark Tracy, Alnylam Pharmaceuticals, Boston, MA	Lymphatic Transport of Drugs Chris Porter, Monash Institute of Pharmaceutical Sciences, Parkville, Australia
11:00-11:30	Membrane/Core Type Nanoparticles for Co-delivery of siRNA and Doxorubicin Leaf Huang, University of North Carolina at Chapel Hill, Chapel Hill, NC	Role of Lipids and Lipoproteins in Modifying the Pharmacokinetics and Tissue Distribution of Hydrophobic Drugs Dion Brocks, University of Alberta, Edmonton, AB
11:30-12:00	Ionizable Cationic Lipids and In Vivo Delivery of siRNA: How Low Can We Go? Michael Hope, AICana Technologies, Vancouver, BC	Engineered Lipid-Based Nanoparticles and Nanocapsules for Overcoming Multi-Drug Resistance in Cancer Russell Mumper, University of North Carolina at Chapel Hill, Chapel Hill, NC
12:00-12:10	Trainee presentation: The Induction of tumor apoptosis in B16 Melanoma Following STAT3 siRNA Delivery With a Lipid-Substituted Polyethylenimine Aws Alshamsan (Co-winner Gattefossé Award), University of Alberta, Edmonton, AB	Trainee presentation: Synthesis and <i>in vitro</i> Evaluation of Peptide Decorated Polymeric Micelles for Paclitaxel Delivery to Human Cancer Cells Mostafa Shahin, University of Alberta, Edmonton, AB
12:20	Lunch & Poster Viewing (Upper and Lower Theatre Lobby)	
1:30-4:30	Session V a (Whistler Ballroom A)	Session V b (Whistler Ballroom B)
	CLINICAL DEVELOPMENT OF NANOMEDICINES Chair: Lawrence Mayer, Celator Pharmaceuticals Corp., Vancouver, BC Co-Chair: Ron Boch, Variation Biotechnologies Inc., Ottawa, ON	TECHNICAL AND REGULATORY ISSUES FOR THE BIOANALYTICAL LABORATORY Chair: Athena Juneson, Vancouver, BC Co-Chair: David Kwok, BRI Biopharmaceutical Research Inc., Vancouver, BC
1:30-2:00	Navigating the Path to Approval with Nanomedicines: Challenges and Opportunities Lawrence Mayer, Celator Pharmaceuticals, Vancouver, BC	Recent Scientific and Regulatory Developments in Preclinical and Clinical Bioanalytical Data Supporting GLP Xiaowei Teng, BRI Biopharmaceutical Research Inc., Vancouver, BC
2:00-2:30	Nanotechnology for Cancer Therapy; Lessons Learned from NCI's Nanotechnology Characterization Lab Scott McNeil, SAIC-Frederick Inc./NCI at Frederick, Frederick, MD	Health Canada and SCC Memorandum of Understanding – A Brief Overview of the Canadian GLP Program Vesna Janic, GLP Inspector for SCC, Vancouver, BC
2:30-3:00	Poster Viewing and Break	
3:00-3:30	Improving a Good Thing: Integrating Preclinical and Clinical Experience in the Development of Next Generation siRNA Products Ian MacLachlan, Tekmira Pharmaceuticals Corporation, Burnaby, BC	Challenges in Regulated Bioanalysis - A Case Study Sanj Devarajan, ratiopharm, Mississauga, ON
3:30-4:00	Regulatory and Scientific Approaches for Nanomedicines Raimar Loebenberg, University of Alberta/Drug Development & Innovation Centre, Edmonton, AB	Quality Management System for Bioanalysis Supporting Clinical Trials Nageshwar Thudi, Ranbaxy Pharmaceuticals Canada Inc., Mississauga, ON
6:00 PM	Pre-Gala Dinner Cocktails & Mixer (Whistler Ballroom)	
7:00 PM	CSPS GALA AWARDS DINNER (Whistler Ballroom)	

Saturday, June 5, 2010	
8:30 AM	Session VI (Whistler Ballroom A)
	CHALLENGE ON HOW TO ALIGN PHARMACEUTICAL DEVELOPMENT WITH PAYOR AND CONSUMER NEEDS Chair: Brian Foster, Health Canada, Ottawa, ON
8:30-9:15	The Need to Take on the Challenge of Alignment of Pharma with Payor Needs Suzanne Taylor, BC Ministry of Health Services, Vancouver, BC
9:15-9:35	Pharmacist Perspective Marnie Mitchell, BC Pharmacist Association, Vancouver, BC
9:35-9:55	Payor Perspective Leza Muir, Blue Cross, Vancouver, BC
9:55-10:15	Payor-Sponsor Scientific Dialogue Mark Ferdinand, Rx&D, Ottawa, ON
10:15-10:35	Through a Glass Darkly – The Future of Pharma Mervyn Turner, Merck & Co. Inc., Merck Research Laboratories, Rahway, NJ
10:35	Panel Discussion - Open Forum
	Closing Remarks - Brian Foster
11:30 AM	Symposium Adjourned

For further information please contact bberekoff@cspscanada.org

Canadian Society for Pharmaceutical Sciences / Journal of Pharmacy & Pharmaceutical Sciences
 3126 Dentistry/Pharmacy Centre / University of Alberta / Edmonton, AB T6G 2N8
 Phone: 780-492-0950 / Fax: 780-492-0951
bberekoff@cspscanada.org / www.cspscanada.org